Introduction: The aim of the study was to evaluate the effect of administration of therapeutic doses of ceftiofur and tulathromycin on the circulating lymphocyte subpopulations in healthy pigs. Material and Methods: The study was conducted on thirty healthy 7- to 10-week-old pigs, assigned to three groups: the TUL group, injected with tulathromycin (n = 10); the CEF group, injected with ceftiofur (n = 10); and the C group, the control with no antibiotic administration (n = 10). Blood samples were collected before, during, and after treatment with antimicrobials. Lymphocyte subpopulations circulating in the blood were determined by immunostaining and flow cytometry analyses. Results: Following administration of a therapeutic dose of tulathromycin, there were no changes in the lymphocyte subpopulations circulating in blood. In contrast, administration of ceftiofur at the recommended dose decreased the absolute number of CD3+, CD21+, CD4+CD8-, CD4-CD8+, and double positive CD4CD8 cells. Conclusion: Results from the study indicate that ceftiofur possesses the ability to modulate the immune system in healthy pigs by decreasing lymphocyte subpopulations circulating in blood.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Altunok V., Yazar E., Elmas M., Traş B., Baş A.L., Cöl, R.: Investigation of haematological and biochemical side effects of tilmicosin in healthy New Zealand rabbits. J Vet Med Series B 2002, 49, 68-70.
2. Bazzoni F., Beutler B.: The tumor necrosis factor ligand and receptor families. New Engl J Med 1996, 334, 1717-1725.
3. Bergeron Y., Ouellet N., Deslauriers A.M., Simard M., Olivier M., Bergeron M.G.: Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice. Antimicrob Agents Chemother 1998, 42, 2527-2533.
4. Chang C.F., Chang L.C., Chang Y.F., Chen M., Chiang T.S.: Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine. J Vet Diagn Invest 2002, 14, 153-157.
5. Chrząstek K., Madej J.P., Mytnik E., Wieliczko A.: The influence of antibiotics on B-cell number, percentage, and distribution in the bursa of Fabricius of newly hatched chicks. Poult Sci 2011, 90, 2723-2729.
6. Chrząstek K., Wieliczko A.: The influence of enrofloxacin, florfenicol, ceftiofur and E. coli LPS interaction on T and B cells subset in chicks. Vet Res Commun 2015, 39, 53-60.
7. Ci X., Li H.Y., Song Y., An Y., Yu Q., Zeng F., Deng X.: Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice. Inflammation 2008, 31, 422-427.
8. Clinical and Laboratory Standards Institute. Reference leukocyte (WBC) differential count (proportional) and evaluation of instrument methods; Approved standard 2007, 27.
9. Committee for Veterinary Medicinal Products Summary Report: Ceftiofur. The European Agency for the Evaluation of Medicinal Products EMEA/CVMP/80785/2006-Final.
10. Committee for Veterinary Medicinal Products Summary Report: Tulathromycin. The European Agency for the Evaluation of Medicinal Products EMEA/MRL/842/2002-Final.
11. Duquette S.C., Fischer C.D., Williams A.C., Sajedy S., Feener T.D., Bhargava A., Reti K.L., Muench G.P., Morck D.W., Allison J., Lucas M.J., Buret A.G.: Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs. Am J Vet Res 2015, 76, 507-519.
12. Er A., Altan F., Cetin G., Dik B., Elmas M., Yazar E.: Assessment of the cardiotoxicity of tulathromycin in rabbits. Acta Vet Hung 2011, 59, 327-335.
13. Evans N.A.: Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease. Vet Ther 2005, 6, 83-95.
14. Fernandez Filho T., Favaro C Jr., Ingberman M., Beirao B.C.B., Inoue A., Gomes L., Caron L.F.: Effect of spray Escherichia coli vaccine on the immunity of poultry. Avian Dis 2013, 57, 671-676.
15. Fischer C.D., Beatty J.K., Duquette S.C., Morck D.W., Lucas M.J., Buret A.G: Direct and indirect anti-inflammatory effects of tulathromycin in bovine macrophages: inhibition of CXCL-8 secretion, induction of apoptosis, and promotion of efferocytosis. Antimicrob Agents Chemother 2013, 57, 1385-1393.
16. Fischer C.D., Beatty J.K., Zvaigzne C.G., Lucas M.J., Buret A.G.: Anti-inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-kappaB signaling and CXCL8 transcription. Antimicrob Agents Chemother 2011, 55, 338-348.
17. Hao Z., Zhao Y., Wu H., Hao L., Ding Z., Yang F., Qu B.: The physiological and biochemical evaluation of tulathromycin premix in pigs. J Anim Vet Adv 2012, 11, 4161-4166.
18. Mangano K., Quattrocchi C., Aiello C., Scalia G., Speciale A., Nicoletti G., Di Marco R.: Immunomodulatory properties of cefaclor: in vivo effect on cytokine release and lymphoproliferative response in rats. J Chemother 2006, 18, 641-647.
19. Nutsch R.G., Hart F.J., Rooney K.A., Weigel D.J., Kilgore W.R., Skogerboe T.L.: Efficacy of tulathromycin injectable solution for the treatment of naturally occurring swine respiratory disease. Vet Ther 2005, 6, 214-224.
20. Pomorska-Mól M., Pejsak Z.: Effect of therapeutic doses of enrofloxacin on circulating lymphocyte subpopulations in pigs. Bull Vet Inst Pulawy 2015, 59, 287-293.
21. Pomorska-Mól M., Czyżewska-Dors E., Kwit K., Wierzchosławki K., Pejsak Z.: Ceftiofur hydrochloride affects the humoral and cellular immune response in pigs after vaccination against swine influenza and pseudorabies. BMC Vet Res 2015, 11, 268.
22. Pomorska-Mól M., Kwit K., Wierzchosławki K., Dors A., Pejsak Z.: The effect of amoxicillin, ceftiofur, doxycycline, tiamulin and tulathromycin on swine humoral immune response induced by erysipelas vaccination. Vet Rec 2016, 178, 559.
23. Pomorska-Mól M., Czyżewska-Dors E., Kwit K., Pejsak Z.: Enrofloxacin decreases IL-6 and TNF-á production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells. J Vet Res 2016 60, 189-193.
24. Ratzinger F., Haslacher H., Poeppl W., Hoermann G., Kovarik J.J., Jutz S., Steinberger P., Burgmann H., Pickl W.F., Schmetterer KG.: Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep 2014, 4, 7438.
25. Villiger P.M., Cronin M.T., Amenomori T., Wachsman W., Lotz M.: IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. J Immunol 1991, 146, 550-559.